UNLOXCYT is an innovative immunotherapy offering hope for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for surgery or radiation. This breakthrough treatment is designed to empower the immune system to target cancer more effectively. UNLOXCYT was approved on December 13, 2024. What is the name of the drug,...
IOMERVU is a newly approved radiographic contrast agent designed to enhance the visibility of blood vessels and organs during medical imaging procedures. It is used in both adults and children for intra-arterial and intravenous imaging, offering precise diagnostics for various medical conditions. IOMERVU was approved on November 27, 2024. What is the name of the...
RAPIBLYK offers a new solution for managing fast heart rates in adults with certain heart rhythm disorders, such as atrial fibrillation or atrial flutter. This short-acting medication is designed for temporary use in a hospital setting to help stabilize heart rhythm safely. RAPIBLYK was approved on RAPIBLYK: A New Option for Heart Rate Control in Atrial Arrhythmias...
ATTRUBY is a newly approved medication offering hope for adults with cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM). It aims to reduce cardiovascular death and hospitalizations in patients with this rare and challenging condition. ATTRUBY was approved on November 22, 2024. What is the name of the drug, and what does it do? ATTRUBY (pronounced...
ZIIHERA is a promising new medication for adults with HER2-positive biliary tract cancer (BTC) that has already been treated but is still progressing. This type of cancer affects the bile ducts or gallbladder, and ZIIHERA offers hope for patients who have limited options. ZIIHERA was approved on November 20, 2024. What is the name of the drug, and what does it do?...
What is the name of the drug and what does it do? Revuforj (pronounced REV-you-forge), generic name revumenib, is a prescription medication used to treat adults and children aged 1 year and older with relapsed or refractory acute leukemia. This treatment is specifically for cases with a lysine methyltransferase 2A (KMT2A) gene translocation, a genetic abnormality...